Browse Studies — Arctuva

Phase 1

Efficacy of Topical Ruxolitinib in Acute Skin GVHD: A Pilot Study

The purpose of this study is to see if ruxolitinib, a Janus Kinase (JAK) 1/2 inhibitor, is safe for people who have acute skin graft versus host disease (GVHD)…

Acute Skin Graft Versus Host Disease (GVHD)

Estimated

~$10 – $5,625

Children's Hospital Medical Center, CincinnatiNCT07801248

Phase 4

The Use of Topical Tranexamic Acid Versus Thrombin Spray for the Management of Split Thickness Skin Graft Recipient Site in Burn Management

Investigators hypothesize that topical tranexamic acid will have better or comparable efficacy to topical thrombin in reducing hematoma formation at the wound …

BurnsSkin Graft Complications

Estimated

~$10 – $6,250

University of Kansas Medical CenterNCT06379724

Phase 4

A Prospective Randomized Split-Site Study of Donor-Site Pain and Appearance Following Pelashield TM Versus Xeroform

The purpose of this research study is to compare the effects (good or bad) of a new skin graft dressing (PelashieldTM) compared to the one traditionally used (…

Skin Graft

Estimated

~$10 – $6,250

Wake Forest University Health SciencesNCT07734519

The Lateral, Anterior, Medial (LAM) Femoral Cutaneous Block: A Case Series Harborview Medical Center, Seattle, WA

Skin donor sites in patients undergoing split-thickness skin grafting surgeries can be very painful postoperatively. This site is most often the anterolateral …

Regional AnesthesiaBurnSkin Grafting

Estimated

~$10 – $750

University of WashingtonNCT07221903